Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SGHT Sight Sciences
11.540-0.490-4.07%
Close
02/03 16:00 ET
11.5400.0000.00%
Post Mkt Price 02/03 16:01 ET
High
11.970
Open
11.760
Turnover
550.94K
Low
11.440
Pre Close
12.030
Volume
47.33K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Stifel Nicolaus Upgrades Sight Sciences (SGHT) to a Buy
Sight Sciences Announces 1,000th TearCare® Customer Installation
MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company") an eyecare technology company focused on creating innovative solutions intended to transform
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in todayâ€s session. Rayonier Advanced Materials Inc. (NYSE:RYAM)
Needham Reaffirms Their Hold Rating on Sight Sciences (SGHT)
Sight Sciences Expects 40% Year-Over-Year Rise in Q4 2022 Revenue; Chief Financial Officer Steps Down
04:50 AM EST, 01/10/2023 (MT Newswires) -- Sight Sciences (SGHT) said Monday it expects Q4 2022 total revenue to be in the range of $20.4 million to $20.6 million, up 40% from the prior year period at
Sight Sciences Expects Q4 Topline to Surge 40% Y/Y
Fly Intel: After-Hours Movers
Sight Sciences: Mack Hicks Stepped Down From the Board
Sight Sciences Sees Q4 Sales $20.4M-$20.6M Vs. $20.12M Est., Sees FY22 Sales $71.2M-$71.4M Vs. $70.93M Est.
Sight Sciences Sees Q4 Sales $20.4M-$20.6M Vs. $20.12M Est., Sees FY22 Sales $71.2M-$71.4M Vs. $70.93M Est.
Sight Sciences : Jesse Selnick, CFO and Treasurer, Has Stepped Dn to Pursue Another Opportunity >SGHT
Company Overview
More
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firm's products include viscosurgical system and trabeculotomy instruments. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
CEO： Mr. Paul Badawi
Market： NASDAQ
Listing Date： 07/15/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet